---
title: "AbbVie Inc. (ABBV.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ABBV.US.md"
symbol: "ABBV.US"
name: "AbbVie Inc."
industry: "Biotechnology"
datetime: "2026-05-19T16:10:23.486Z"
locales:
  - [en](https://longbridge.com/en/quote/ABBV.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ABBV.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ABBV.US.md)
---

# AbbVie Inc. (ABBV.US)

## Company Overview

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.abbvie.com](https://www.abbvie.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: C (0.57)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 64 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.50% |  |
| Net Profit YoY | -13.48% |  |
| P/B Ratio | -55.59 |  |
| Dividend Ratio | 3.22% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 369984084645.61 |  |
| Revenue | 62819000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -137.32% | E |
| Profit Margin | 5.79% | B |
| Gross Margin | 71.88% | A |
| Revenue YoY | 9.50% | B |
| Net Profit YoY | -13.48% | D |
| Total Assets YoY | 0.22% | D |
| Net Assets YoY | -552.26% | E |
| Cash Flow Margin | 590.38% | A |
| OCF YoY | 9.50% | B |
| Turnover | 0.46 | C |
| Gearing Ratio | 104.85% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - AbbVie Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.50%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.48%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-55.59",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.22%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "369984084645.61",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "62819000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-137.32%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "5.79%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "71.88%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "9.50%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.48%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.22%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-552.26%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "590.38%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "9.50%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.46",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "104.85%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 102.92 | 59/386 | 165.63 | 99.16 | 82.90 |
| PB | -55.59 | 540/386 | 237.38 | 234.51 | 230.73 |
| PS (TTM) | 5.89 | 123/386 | 6.75 | 6.38 | 5.86 |
| Dividend Yield | 3.22% | 3/386 | 3.34% | 3.05% | 2.88% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **33**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 16 | 48% |
| Overweight | 8 | 24% |
| Hold | 8 | 24% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 214.76 |
| Highest Target | 328.00 |
| Lowest Target | 184.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ABBV.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ABBV.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ABBV.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ABBV.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**